Holen Sie sich die Stockscreener-App
8.33
4.69%
-0.41
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Equities Analysts Offer Predictions for STOK Q1 Earnings - Defense World
HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
Trading (STOK) With Integrated Risk Controls - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital - Defense World
Stoke Therapeutics’ Collaboration with BioGen - Global Legal Chronicle
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – Here’s Why - Defense World
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright - Defense World
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - BioSpace
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright - Smartphone Magazine
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
BTIG maintains Stoke Therapeutics stock with $29 target By Investing.com - Investing.com UK
HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating - Marketscreener.com
Biogen And Stoke Therapeutics Enter Into Collaboration -February 18, 2025 at 10:00 am EST - Marketscreener.com
Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating - TipRanks
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen -February 18, 2025 at 09:39 am EST - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Biogen, Stoke partner for Dravet syndrome treatment By Investing.com - Investing.com South Africa
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha
Sector Update: Health Care Stocks Softer Wednesday Afternoon -February 12, 2025 at 01:47 pm EST - Marketscreener.com
SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Sector Update: Health Care Stocks Retreat Late Afternoon -February 12, 2025 at 03:54 pm EST - Marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat
Long Term Trading Analysis for (STOK) - Stock Traders Daily
Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater
STOK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2%Here's Why - MarketBeat
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? - MSN
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts - Armenian Reporter
Stoke Therapeutics Inc (STOK) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Stoke Therapeutics Inc: Rising -28.33% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Trading Day Review: Stoke Therapeutics Inc (STOK) Gains Momentum, Closing at 12.60 - The Dwinnex
FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs - MarketBeat
STOK (Stoke Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Morgan Stanley Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6.9%Should You Buy? - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.6%What's Next? - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (STOK) - Stock Traders Daily
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):